ID

38921

Description

Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone; ODM derived from: https://clinicaltrials.gov/show/NCT01512108

Link

https://clinicaltrials.gov/show/NCT01512108

Keywords

Versions (1)
  1. 11/13/19 11/13/19 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

November 13, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Diabetes NCT01512108

English

Eligibility Diabetes NCT01512108

1 forms  
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT01512108
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
informed consent obtained before any trial-related activities (trial-related activities are any procedures that would not have been performed during normal management of the subject.)
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
japanese subjects with type 2 diabetes on monotherapy with an oad (either glinide, metformin, a-glucosidase inhibitor or thiazolidinedione) within approved japanese labelling in addition to diet and exercise therapy. total daily dose and type of drug should have remained unchanged for at least 8 weeks prior to visit 1
Description

Japanese | Diabetes Mellitus, Non-Insulin-Dependent | Antidiabetics Oral | Glinide | Metformin | alpha-Glucosidase Inhibitors | Thiazolidinediones | Diet therapy | Exercise | Cumulative Dose Daily unchanged | Pharmaceutical Preparations Type unchanged

Data type

boolean

Alias
UMLS CUI [1]
C1556094
UMLS CUI [2]
C0011860
UMLS CUI [3,1]
C0935929
UMLS CUI [3,2]
C1527415
UMLS CUI [4]
C2266929
UMLS CUI [5]
C0025598
UMLS CUI [6]
C1299007
UMLS CUI [7]
C1257987
UMLS CUI [8]
C0012159
UMLS CUI [9]
C0015259
UMLS CUI [10,1]
C2986497
UMLS CUI [10,2]
C0332173
UMLS CUI [10,3]
C0442739
UMLS CUI [11,1]
C0013227
UMLS CUI [11,2]
C0332307
UMLS CUI [11,3]
C0442739
type 2 diabetes mellitus (clinically diagnosed) for at least 6 months
Description

Non-Insulin-Dependent Diabetes Mellitus Disease length

Data type

boolean

Alias
UMLS CUI [1,1]
C0011860
UMLS CUI [1,2]
C0872146
hba1c between 7.0-10.0% (both inclusive)
Description

Hemoglobin A1c measurement

Data type

boolean

Alias
UMLS CUI [1]
C0474680
body mass index (bmi) below 40.0 kg/m^2
Description

Body mass index

Data type

boolean

Alias
UMLS CUI [1]
C1305855
outpatients who have no plans for an educational hospitalisation for the purpose of glycaemic control. however, hospitalisation for training of self-injection from visit 2 that is for no longer than one week is allowed
Description

Outpatients | Absence Hospitalization Education Glycaemia control

Data type

boolean

Alias
UMLS CUI [1]
C0029921
UMLS CUI [2,1]
C0332197
UMLS CUI [2,2]
C0019993
UMLS CUI [2,3]
C0030688
UMLS CUI [2,4]
C3267174
subjects able and willing to perform self-monitoring of plasma glucose (smpg)
Description

Plasma Glucose Measurement Self Perform

Data type

boolean

Alias
UMLS CUI [1,1]
C0202042
UMLS CUI [1,2]
C0036588
UMLS CUI [1,3]
C0884358
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
subjects with known or previous malignant tumor and are strongly suspected of recurrence (except basal cell skin cancer or squamous cell skin cancer)
Description

Malignant Neoplasms | Recurrence Suspected | Exception Basal cell carcinoma | Exception Squamous cell carcinoma of skin

Data type

boolean

Alias
UMLS CUI [1]
C0006826
UMLS CUI [2,1]
C0034897
UMLS CUI [2,2]
C0750491
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0007117
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0553723
calcitonin above or equal to 160 pg/ml
Description

Calcitonin measurement

Data type

boolean

Alias
UMLS CUI [1]
C0201924
personal history of non-familial medullary thyroid carcinoma
Description

Medullary carcinoma of thyroid

Data type

boolean

Alias
UMLS CUI [1]
C0238462
family or personal history of multiple endocrine neoplasia type 2 (men-2) or familial medullary thyroid carcinoma (fmtc)
Description

Family history of multiple endocrine neoplasia Type | Multiple Endocrine Neoplasia Type | Familial medullary thyroid carcinoma

Data type

boolean

Alias
UMLS CUI [1,1]
C4039247
UMLS CUI [1,2]
C0332307
UMLS CUI [2,1]
C0027662
UMLS CUI [2,2]
C0332307
UMLS CUI [3]
C1833921
history of chronic pancreatitis or idiopathic acute pancreatitis
Description

Pancreatitis, Chronic | Idiopathic acute pancreatitis

Data type

boolean

Alias
UMLS CUI [1]
C0149521
UMLS CUI [2]
C0341461
recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event during the last 12 months) or hypoglycaemic unawareness as judged by the investigator or hospitalisation for diabetic ketoacidosis during the previous 6 months
Description

Recurrent severe hypoglycemia | Hypoglycaemic episode Severe Quantity | Loss of hypoglycemic warning | Hospitalization Diabetic Ketoacidosis

Data type

boolean

Alias
UMLS CUI [1]
C0342316
UMLS CUI [2,1]
C0745153
UMLS CUI [2,2]
C0205082
UMLS CUI [2,3]
C1265611
UMLS CUI [3]
C0342317
UMLS CUI [4,1]
C0019993
UMLS CUI [4,2]
C0011880
treatment with glp-1 receptor agonist or dipeptidyl peptidase 4 (dpp-4) inhibitor within 12 weeks prior to visit 1
Description

GLP-1 Receptor Agonist | Dipeptidyl Peptidase 4 Inhibitors

Data type

boolean

Alias
UMLS CUI [1]
C2917359
UMLS CUI [2]
C2917254
having contraindications to liraglutide and any of the oads (according to japanese labelling)
Description

Medical contraindication Liraglutide | Medical contraindication Antidiabetics Oral

Data type

boolean

Alias
UMLS CUI [1,1]
C1301624
UMLS CUI [1,2]
C1456408
UMLS CUI [2,1]
C1301624
UMLS CUI [2,2]
C0935929
UMLS CUI [2,3]
C1527415
Back to the top of the page

Similar models

Eligibility Diabetes NCT01512108

1 forms
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT01512108
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Informed Consent
Item
informed consent obtained before any trial-related activities (trial-related activities are any procedures that would not have been performed during normal management of the subject.)
boolean
C0021430 (UMLS CUI [1])
Japanese | Diabetes Mellitus, Non-Insulin-Dependent | Antidiabetics Oral | Glinide | Metformin | alpha-Glucosidase Inhibitors | Thiazolidinediones | Diet therapy | Exercise | Cumulative Dose Daily unchanged | Pharmaceutical Preparations Type unchanged
Item
japanese subjects with type 2 diabetes on monotherapy with an oad (either glinide, metformin, a-glucosidase inhibitor or thiazolidinedione) within approved japanese labelling in addition to diet and exercise therapy. total daily dose and type of drug should have remained unchanged for at least 8 weeks prior to visit 1
boolean
C1556094 (UMLS CUI [1])
C0011860 (UMLS CUI [2])
C0935929 (UMLS CUI [3,1])
C1527415 (UMLS CUI [3,2])
C2266929 (UMLS CUI [4])
C0025598 (UMLS CUI [5])
C1299007 (UMLS CUI [6])
C1257987 (UMLS CUI [7])
C0012159 (UMLS CUI [8])
C0015259 (UMLS CUI [9])
C2986497 (UMLS CUI [10,1])
C0332173 (UMLS CUI [10,2])
C0442739 (UMLS CUI [10,3])
C0013227 (UMLS CUI [11,1])
C0332307 (UMLS CUI [11,2])
C0442739 (UMLS CUI [11,3])
Non-Insulin-Dependent Diabetes Mellitus Disease length
Item
type 2 diabetes mellitus (clinically diagnosed) for at least 6 months
boolean
C0011860 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
Hemoglobin A1c measurement
Item
hba1c between 7.0-10.0% (both inclusive)
boolean
C0474680 (UMLS CUI [1])
Body mass index
Item
body mass index (bmi) below 40.0 kg/m^2
boolean
C1305855 (UMLS CUI [1])
Outpatients | Absence Hospitalization Education Glycaemia control
Item
outpatients who have no plans for an educational hospitalisation for the purpose of glycaemic control. however, hospitalisation for training of self-injection from visit 2 that is for no longer than one week is allowed
boolean
C0029921 (UMLS CUI [1])
C0332197 (UMLS CUI [2,1])
C0019993 (UMLS CUI [2,2])
C0030688 (UMLS CUI [2,3])
C3267174 (UMLS CUI [2,4])
Plasma Glucose Measurement Self Perform
Item
subjects able and willing to perform self-monitoring of plasma glucose (smpg)
boolean
C0202042 (UMLS CUI [1,1])
C0036588 (UMLS CUI [1,2])
C0884358 (UMLS CUI [1,3])
Item Group
C0680251 (UMLS CUI)
Malignant Neoplasms | Recurrence Suspected | Exception Basal cell carcinoma | Exception Squamous cell carcinoma of skin
Item
subjects with known or previous malignant tumor and are strongly suspected of recurrence (except basal cell skin cancer or squamous cell skin cancer)
boolean
C0006826 (UMLS CUI [1])
C0034897 (UMLS CUI [2,1])
C0750491 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0007117 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0553723 (UMLS CUI [4,2])
Calcitonin measurement
Item
calcitonin above or equal to 160 pg/ml
boolean
C0201924 (UMLS CUI [1])
Medullary carcinoma of thyroid
Item
personal history of non-familial medullary thyroid carcinoma
boolean
C0238462 (UMLS CUI [1])
Family history of multiple endocrine neoplasia Type | Multiple Endocrine Neoplasia Type | Familial medullary thyroid carcinoma
Item
family or personal history of multiple endocrine neoplasia type 2 (men-2) or familial medullary thyroid carcinoma (fmtc)
boolean
C4039247 (UMLS CUI [1,1])
C0332307 (UMLS CUI [1,2])
C0027662 (UMLS CUI [2,1])
C0332307 (UMLS CUI [2,2])
C1833921 (UMLS CUI [3])
Pancreatitis, Chronic | Idiopathic acute pancreatitis
Item
history of chronic pancreatitis or idiopathic acute pancreatitis
boolean
C0149521 (UMLS CUI [1])
C0341461 (UMLS CUI [2])
Recurrent severe hypoglycemia | Hypoglycaemic episode Severe Quantity | Loss of hypoglycemic warning | Hospitalization Diabetic Ketoacidosis
Item
recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event during the last 12 months) or hypoglycaemic unawareness as judged by the investigator or hospitalisation for diabetic ketoacidosis during the previous 6 months
boolean
C0342316 (UMLS CUI [1])
C0745153 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
C0342317 (UMLS CUI [3])
C0019993 (UMLS CUI [4,1])
C0011880 (UMLS CUI [4,2])
GLP-1 Receptor Agonist | Dipeptidyl Peptidase 4 Inhibitors
Item
treatment with glp-1 receptor agonist or dipeptidyl peptidase 4 (dpp-4) inhibitor within 12 weeks prior to visit 1
boolean
C2917359 (UMLS CUI [1])
C2917254 (UMLS CUI [2])
Medical contraindication Liraglutide | Medical contraindication Antidiabetics Oral
Item
having contraindications to liraglutide and any of the oads (according to japanese labelling)
boolean
C1301624 (UMLS CUI [1,1])
C1456408 (UMLS CUI [1,2])
C1301624 (UMLS CUI [2,1])
C0935929 (UMLS CUI [2,2])
C1527415 (UMLS CUI [2,3])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial